Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solvent-exposed cysteine residues on epidermal and cytosolic proteins are highly reactive nucleophilic sites that serve as primary targets for both toxic electrophiles and targeted covalent drugs. These residues possess a thiol side chain whose reactivity is often modulated by the local protein environment, allowing for site-specific modifications such as alkylation or redox-based signaling. In toxicology, they are the principal targets of vesicants like sulfur mustard, which cross-links proteins such as p53 and keratins in the skin, leading to severe blistering and cell death. In therapeutic contexts, these residues are exploited by covalent inhibitors to irreversibly bind to specific kinases, providing enhanced efficacy and selectivity. The broad distribution of these reactive sites across the cysteinome makes them central to cellular homeostasis but also poses challenges regarding off-target toxicity and immunogenicity.
Covalent alkylation and Michael addition to nucleophilic thiol groups
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solvent-exposed cysteine residues on epidermal and cytosolic proteins.